Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Melanotan II at a glance
- What it is
- Synthetic cyclic heptapeptide, a non-selective melanocortin receptor (MC1R–MC5R) agonist
- Researched for
- Melanogenesis (skin pigmentation) in early research; MC4R-linked effects on libido and appetite reported
- Commonly reported range
- ~250–500 mcg per dose in community reports
- Route reported
- Subcutaneous injection
- Reported frequency
- Daily during a loading phase, then 1–3x weekly for maintenance
- Reported cycle
- ~1–2 week loading, then intermittent maintenance in community protocols
- Plasma half-life
- Reported short, roughly 30 minutes to ~1 hour
- Regulatory status
- Not FDA-approved for any use; sold as research-only; unapproved in US/UK/EU
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH) that acts as a non-selective agonist across the melanocortin receptor family (MC1R through MC5R). Its best-characterized action is at MC1R on melanocytes, where receptor activation raises intracellular cyclic AMP and upregulates tyrosinase, the rate-limiting enzyme of melanin synthesis, in reported research this drives increased eumelanin production and skin darkening. Because it is non-selective, it also engages MC3R and MC4R in the central nervous system, and this MC4R activity is the reported basis for the appetite-suppressing and sexual-arousal effects that distinguish it from the more MC1R-selective afamelanotide (Melanotan I). The related fragment bremelanotide (PT-141) was developed specifically around this MC4R sexual-response pathway. These are described mechanisms from preclinical and early research, not established therapeutic outcomes.
Researched effects
In research and community reports, Melanotan II is associated with increased skin pigmentation (tanning) with reduced UV exposure, and, via central melanocortin activity, reported appetite suppression and increased sexual arousal. These are research findings and community-reported observations, not guaranteed outcomes, and human data are limited and largely uncontrolled. Individual responses reportedly vary widely with skin type, dose, and UV exposure.
Evidence & regulatory status
- Evidence: Early-phase academic research explored melanocortin analogs for photoprotection and melanogenesis; most published Melanotan II human data are small studies, case reports, and community observations rather than large controlled trials.
- Regulatory: Melanotan II has no FDA approval for any indication and is not approved in the UK, EU, or other major jurisdictions; regulators (including the FDA and UK MHRA) have issued warnings against unlicensed products.
- Research-use: Material sold under this name is intended for laboratory and educational research use only and is not a medicine or cosmetic; nothing here endorses human use.
Dosage — reported ranges (overview)
The figures below are examples of what is reported in community protocols and vendor literature, not a recommendation and not a personal dose. Reported protocols commonly describe a loading phase of roughly 250 mcg per subcutaneous dose daily for about 1–2 weeks, sometimes titrated toward 500 mcg if tolerated, followed by a maintenance phase of about 500 mcg one to three times per week. Because MT-II can cause nausea and other effects, community reports frequently mention starting low. These are descriptions of reported practice for educational context only.
A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.
Reconstitution — bac-water math
Melanotan II ships as a lyophilized powder that is reconstituted with bacteriostatic water and measured on a U-100 insulin syringe, where 100 units = 1 mL. For a mcg-dosed peptide, the key figure is concentration in mcg/mL: with a V-mg vial and W mL of water, concentration = (V x 1000) / W mcg/mL, and the units to draw for a dose of D mcg = round(D / concentration x 100). Worked example: a representative 10 mg vial reconstituted with 2 mL of bacteriostatic water gives (10 x 1000) / 2 = 5,000 mcg/mL; a 500 mcg example dose is then 500 / 5000 x 100 = 10 units on a U-100 syringe. This is concentration math only, not a personal dose.
| Bac water added | Concentration | 250 mcg dose | 500 mcg dose |
|---|
| 1 mL | 10,000 mcg/mL | 2.5 units | 5 units |
| 2 mL | 5,000 mcg/mL | 5 units | 10 units |
| 3 mL | 3,333 mcg/mL | 7.5 units | 15 units |
This is concentration math, not a dose recommendation.
Injection / administration basics
In reported protocols, Melanotan II is administered subcutaneously using a small insulin syringe, typically into the fat of the abdomen with the site rotated between injections. Bacteriostatic water is the commonly described diluent, added slowly against the vial wall rather than directly onto the powder, and the vial is gently swirled rather than shaken. This describes reported handling practice for research context and is not medical or administration advice.
Half-life & frequency rationale
Melanotan II is reported to have a short plasma half-life, with sources citing roughly 30 minutes to about 1 hour. This short duration is the reason daily dosing appears in loading-phase community protocols, while the pigmentation effect itself is reported to persist much longer because melanin, once produced, remains in the skin.
Side effects, safety & contraindications
Commonly reported side effects include nausea (especially after early doses), facial flushing, appetite suppression, spontaneous erections in males, and darkening of existing moles and freckles. Published case literature has associated Melanotan II with concerning events including new or changing melanocytic nevi and reported melanoma, priapism, rhabdomyolysis, and renal infarction. Human safety data are limited and the compound is unapproved, so its long-term safety is not established. These are reported findings, not an exhaustive list, and nothing here is medical advice.
Stacking — overview
Because it is non-selective across melanocortin receptors, Melanotan II is most often discussed in the community alongside compounds that target overlapping pathways or complementary goals. The pairings below reflect commonly reported combinations for educational context only, not recommendations, and combining unapproved compounds adds unknown risks.
Melanotan II + PT-141
MT-II (pigmentation, general melanocortin activity) with PT-141/bremelanotide (MC4R-focused sexual-arousal peptide), a frequently discussed melanocortin pairing
Melanotan II + BPC-157
MT-II with BPC-157, community-reported for general recovery support alongside a pigmentation protocol
Melanotan II + GHK-Cu
MT-II with the copper peptide GHK-Cu, reported together in skin- and appearance-focused routines
Stacking across compounds
The overview above covers Melanotan II. The cross-compound material — which pairings are redundant rather than additive, where interaction risk is documented versus merely unstudied, and the blend arithmetic worked end to end — lives in the Peptide Stacking Guide, which is free to read in outline and $39 in full (included with All-Access Lifetime).
Included with this guide
The Melanotan II Stacking Module
The overview above is the free summary. The Melanotan II Stacking Module goes through each combination in depth — the mechanism-level reason it is proposed, what is actually reported in practice, and the cautions specific to that pairing — plus what to avoid and why. Included with Melanotan II Standard Access.
- How to think about stacking Melanotan II — 4 principles
- 3 combinations covered in detail
- What to avoid, and why — 3 items
- Combination-specific cautions
Combinations covered: Melanotan II + PT-141, Melanotan II + GHK-Cu, Melanotan II + BPC-157.
For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.
Storage & handling
- Lyophilized (powder): store sealed and protected from light; refrigeration is commonly recommended, and cool freezer storage is reported for long-term stability before reconstitution.
- Reconstituted (in bacteriostatic water): keep refrigerated (about 2–8 C), protect from light, and use within a few weeks per common handling guidance.
References
Compiled from melanocortin-receptor pharmacology literature, published Melanotan II case reports, and regulatory warnings from agencies including the FDA and UK MHRA; presented for educational use only and not medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Guide FAQ
Quick answers about guide scope, access, and educational use context.
Is Melanotan II approved or legal to use?
No. Melanotan II is not approved by the FDA or by regulators in the UK, EU, or other major jurisdictions for any use. It is sold as a research chemical only, and health agencies have warned against unlicensed products. This guide is educational and not an endorsement of human use.
How is Melanotan II different from Melanotan I?
Melanotan I (afamelanotide) is more selective for MC1R and is an approved drug in some regions for a rare photosensitivity disorder. Melanotan II is non-selective across melanocortin receptors, which is why it is reported to also affect appetite and sexual arousal via MC3R/MC4R, and it is not approved anywhere.
What dose is reported for Melanotan II?
Community protocols commonly describe roughly 250 mcg per subcutaneous dose during a loading phase and about 500 mcg for maintenance one to three times weekly. These are reported examples for educational context, not a recommendation or a personal dose.
Why does it need a loading phase?
Its plasma half-life is reported to be short (roughly 30 minutes to an hour), so daily dosing appears during the loading phase in community reports, while the visible pigmentation, once melanin is produced, is reported to persist much longer.
What are the main reported risks?
Reported side effects include nausea, flushing, appetite loss, and darkening of moles. Case reports have linked it to changing moles and melanoma, priapism, and rare vascular and muscle events. Human safety data are limited and long-term safety is not established.
Compliance and trust notes
- Educational content only; no personalized health or outcome claims.
- No personalized use recommendation outputs.
- Use this material for general learning and research-context literacy.
